Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747190 | 0.92 | GRIN2B (0.52) | GRIN2BGRIN1PPARDMAOAMAOB | |
| SCHEMBL1746466 | 0.84 | GRIN1 (0.61) | GRIN2BGRIN1 | |
| SCHEMBL3970687 | 0.84 | GRIN1 (0.61) | GRIN2BGRIN1 | |
| SCHEMBL3965085 | 0.84 | GRIN1 (0.61) | GRIN2BGRIN1 | |
| SCHEMBL1745525 | 0.78 | FFAR1 (0.60) | PPARD | |
| SCHEMBL19216402 | 0.77 | GRIN2B (0.81) | GRIN2BGRIN1GRM5SIGMAR1 | |
| SCHEMBL16539932 | 0.76 | MAOB (0.53) | PPARDMAOB | |
| SCHEMBL9534252 | 0.76 | PPARD (0.51) | PPARDMAOAMAOB | |
| SCHEMBL1745404 | 0.75 | FFAR1 (0.47) | GRIN2BGRIN1PPARD | |
| SCHEMBL1744975 | 0.75 | HRH3 (0.47) | GRIN2BGRIN1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | GRIN2B 1276/4885GRIN1 829/4885PPARD 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.